`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`WOCKHARDT BIO AG,
`TEVA PHARMACEUTICALS USA, INC.,
`AUROBINDO PHARMA U.S.A., INC.,
`Petitioners,
`
`v.
`
`ASTRAZENECA AB,
`Patent Owner.
`
`
`
`Case: IPR2015-013401
`U.S. Patent No. RE44,186
`
`
`ASTRAZENECA’S UNOPPOSED MOTION FOR
`PRO HAC VICE ADMISSION OF DANIEL M. SILVER
`UNDER 37 C.F.R. § 42.10(c)
`
`
`
`
`
`1 Petitioner Wockhardt from IPR2016-01029, Petitioner Teva from IPR2016-
`01122, and Petitioner Aurobindo from IPR2016-01117 have been added as
`Petitioners to this proceeding.
`
`
`
`
`
`
`
`
`
`
`
`
`
`I.
`
`STATEMENT OF PRECISE RELIEF REQUESTED
`Pursuant to 37 C.F.R. § 42.10(c) authorizing motions for pro hac vice
`
`admission of back-up counsel, Patent Owner AstraZeneca AB requests that the
`
`Patent Trial and Appeal Board (the “Board”) admit Daniel M. Silver pro hac vice
`
`in this proceeding, IPR2015-01340, for the limited purpose of taking a deposition
`
`in this proceeding.
`
`II.
`
`STATEMENT OF FACTS SHOWING GOOD CAUSE FOR THE
`BOARD TO RECOGNIZE BACK-UP COUNSEL PRO HAC VICE
`DURING THE PROCEEDING
`
`In accordance with 37 C.F.R. § 42.10(c), the Board may recognize counsel
`
`pro hac vice subject to the condition that lead counsel be a registered practitioner
`
`and to any other conditions that the Board may impose. Section 42.10(c) provides
`
`that “where the lead counsel is a registered practitioner, a motion to appear pro hac
`
`vice by counsel who is not a registered practitioner may be granted upon showing
`
`that counsel is an experienced litigating attorney and has an established familiarity
`
`with the subject matter at issue in the proceeding.” See also Unified Patents v.
`
`Parallel Iron, IPR2013-00639, Paper 7 (Oct. 15, 2013). The following facts
`
`establish good cause for the Board to recognize Daniel M. Silver pro hac vice in
`
`this proceeding:
`
`1.
`
`As a partner at McCarter & English, Mr. Silver is an experienced
`
`litigator, and has established familiarity with the subject matter at issue in this
`
`
`
`proceeding from his participation in co-pending litigation involving the subject
`
`patent. Specifically, U.S. Patent No. RE44,186 is currently asserted by Patent
`
`Owner AstraZeneca AB in co-pending litigation, in the District of Delaware,
`
`AtraZeneca AB v. Aurobindo Pharma Ltd., et al., 14-cv-00664 (D. Del. 2014) (“the
`
`co-pending litigation”). Mr. Silver is a member of the Delaware Bar in good
`
`standing, has been representing the Patent Owner in the co-pending litigation and
`
`has been actively involved in the case. Mr. Silver has not applied to appear pro
`
`hac vice in any other Board, or United States Patent and Trademark Office
`
`(“USPTO”) proceeding, over the last three years.
`
`2.
`
`As part of his participation in co-pending litigation involving the
`
`subject patent, Mr. Silver has become intimately familiar with the financial-related
`
`issues in this proceeding. In fact, Mr. Silver directed and cross-examined the
`
`financial experts during the September trial of the co-pending litigation. Patent
`
`Owner wishes to apply Mr. Silver’s knowledge as counsel in the deposition of
`
`Petitioners’ financial expert in this proceeding. Admission of Mr. Silver pro hac
`
`vice will enable Patent Owner to avoid unnecessary expense and duplication of
`
`work between this proceeding and the co-pending litigation.
`
`3.
`
`Patent Owner’s lead counsel, Charlie Lipsey, is a registered
`
`practitioner and Mr. Silver is an experienced litigation attorney having established
`
`familiarity with the subject matter at issue in this proceeding. Therefore, Patent
`
`2
`
`
`
`Owner respectfully submits that there is good cause for the Board to recognize Mr.
`
`Silver as counsel pro hac vice during this proceeding.
`
`4.
`
`This Motion for Pro Hac Vice Admission is supported by a
`
`Declaration of Mr. Silver (Exhibit 2216).
`
`5.
`
`Counsel for Petitioners do not oppose Mr. Silver appearing pro hac
`
`vice during this proceeding for the limited purpose of taking a deposition.
`
`III. CONCLUSION
`For the foregoing reasons, Patent Owner respectfully requests that the Board
`
`admit Daniel M. Silver pro hac vice in this proceeding.
`
`Dated: November 16, 2016
`
`Respectfully submitted,
`
`
`
`By: / Anthony A. Hartmann /
`
`Anthony A. Hartmann
`Reg. No. 43,662
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER, LLP
`901 New York Avenue, NW Washington,
`DC 20001-4413
`(202) 408-4000
`
`Counsel for Patent Owner in
`IPR2015-01340
`
`3
`
`
`
`The undersigned certifies that copies of the foregoing ASTRAZENECA’S
`
`
`
`
`UNOPPOSED MOTION FOR PRO HAC VICE ADMISSION OF DANIEL
`
`M. SILVER UNDER 37 C.F.R. § 42.10(c) and AstraZeneca Exhibit 2216
`
`were served electronically via e-mail on November 16, 2016, in its entirety to the
`
`following:
`
`Counsel for Petitioner Mylan Pharmaceuticals Inc.:
`
`
`
`
`
`
`
`
`
`
`
`
`
`Counsel for Petitioner Wockhardt BIO AG.:
`
`
`
`
`Counsel for Petitioner Teva Pharmaceuticals U.S.A., Inc..:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Steven W. Parmelee
`sparmelee@wsgr.com
`
`Richard Torczon
`rtorczon@wsgr.com
`
`Jad A. Mills
`jmills@wsgr.com
`
`Douglas H. Carsten
`dcarsten@wsgr.com
`
`Patrick Gallagher
`PCGallagher@duanemorris.com
`
`Gary Speier
`gspeier@carlsoncaspers.com
`
`Iain McIntyre
`imcintyre@carlsoncaspers.com
`
`4
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Counsel for Petitioner Aurobindo Pharma U.S.A., Inc..:
`
`
`
`
`
`
`
`
`Dated: November 16, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Sailesh K. Patel
`SPatel@schiffhardin.com
`
`George Yu
`GYu@schiffhardin.com
`
`By: /Lauren K. Young/
`Lauren K. Young
`Litigation Legal Assistant
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, L.L.P.
`
`5
`
`